RxDoctor Payments Data

Joshua Larned, MD

Cardiovascular Disease · Fort Lauderdale, FLNPI 1023293537

Payments from drug & device makers

$421,908in general payments, 2019–2025

Across 250 payments — averaging $1687.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$119K
  • Cvrx, Inc.$74K
  • Boehringer Ingelheim$52K
  • Novartis$49K
  • AstraZeneca$32K
  • Pfizer$25K
  • plus $71K from 20 others

What the payments were for

  • Speaking & faculty fees$49,36589%
  • Travel & lodging$2,4974%
  • Food & beverage$3,8467%
  • Education$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$421,908 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$346,108
Medicare patients
1,851
Services billed
5,223

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban214$249,290
XareltoRivaroxaban100$105,906
EntrestoSacubitril/Valsartan62$72,765
JardianceEmpagliflozin57$56,450
Repatha SureclickEvolocumab47$53,482
FarxigaDapagliflozin Propanediol20$18,243
Praluent PenAlirocumab15$12,054
Metoprolol Succinate299$5,038
Valsartan134$4,250
Rosuvastatin Calcium207$2,634
Atorvastatin Calcium237$2,277
Ranolazine ErRanolazine13$2,027
Carvedilol135$1,359
Losartan Potassium91$1,171
Amlodipine Besylate146$1,147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$24,751$249,290214 claims
Johnson & JohnsonXarelto$122$105,906100 claims
NovartisEntresto$49,303$72,76562 claims
Boehringer IngelheimJardiance$51,517$56,45057 claims
AstraZenecaFarxiga$32,240$18,24320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Fort Lauderdale

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →